This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ponka P. Cellular iron metabolism. Kidney Int 1999; 55: 2–11.PonkaP.Cellular iron metabolism199955211Search in Google Scholar
Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H. Iron metabolism and iron supplementation in cancer patients [published correction appears in Wien Klin Wochenschr 2015 Dec; 127 (23–24): 920–1]. Wien Klin Wochenschr 2015; 127 (23–24): 907–19.LudwigHEvstatievRKornekGAaproMBauernhoferTBuxhofer-AuschVFridrikMGeisslerDGeisslerKGisslingerHKollerEKopetzkyGLangARumpoldHSteurerMKamaliHLinkH.Iron metabolism and iron supplementation in cancer patients [published correction appears in Wien Klin Wochenschr 2015 Dec; 127 (23–24): 920–1]201512723–2490719Search in Google Scholar
Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886–92.LudwigHMüldürEEndlerGHüblWPrevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia201324188692Search in Google Scholar
Ludwig H, Müldür E, Endler G, Hübl W, Moneuse P, Klement B. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96 (Suppl 2): 409.LudwigHMüldürEEndlerGHüblWMoneusePKlementB.High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status201196Suppl 2409Search in Google Scholar
John Hopkins Medicine [Internet]. Pancreatic Cancer Prognosis; [cited 2023 Nov 07]. Available from: http://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosisPancreatic Cancer Prognosis[cited 2023 Nov 07]. Available from: http://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosisSearch in Google Scholar
Cancer Treatment Centers of America [Internet]. Pancreatic cancer stages; [updated 2022 May 10; cited 2023 Nov 07]. Available from https://www.cancercenter.com/cancer-types/pancreatic cancer/stages#:~:text=Most%20often%2C%20pancreatic%20cancer%20spreads,Abdominal%20painPancreatic cancer stages[updated 2022 May 10; cited 2023 Nov 07]. Available from https://www.cancercenter.com/cancer-types/pancreatic cancer/stages#:~:text=Most%20often%2C%20pancreatic%20cancer%20spreads,Abdominal%20painSearch in Google Scholar
Cipora E, Czerw A, Partyka O, Pajewska M, Badowska-Kozakiewicz A, Fudalej M, Sygit K, Kaczmarski M, Krzych-Fałta E, Jurczak A, Karakiewicz-Krawczyk K, Wieder-Huszla S, Banaś T, Bandurska E, Ciećko W, Kosior DA, Kułak P, Deptała A. Quality of Life in Patients with Pancreatic Cancer-A Literature Review. Int J Environ Res Public Health 2023; 20 (6): 4895.CiporaECzerwAPartykaOPajewskaMBadowska-KozakiewiczAFudalejMSygitKKaczmarskiMKrzych-FałtaEJurczakAKarakiewicz-KrawczykKWieder-HuszlaSBanaśTBandurskaECiećkoWKosiorDAKułakPDeptałaAQuality of Life in Patients with Pancreatic Cancer-A Literature Review20232064895Search in Google Scholar
Jiang S, Fagman JB, Ma Y, Liu J, Vihav C, Engstrom C, Liu B, Chen C. A comprehensive review of pancreatic cancer and its therapeutic challenges. Aging (Albany NY) 2022; 14 (18): 7635–49.JiangSFagmanJBMaYLiuJVihavCEngstromCLiuBChenC.A comprehensive review of pancreatic cancer and its therapeutic challenges20221418763549Search in Google Scholar
Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 2016; 57: 10–22.ConroyTBachetJBAyavAHuguetFLambertACaramellaCMaréchalRVan LaethemJLDucreuxM.Current standards and new innovative approaches for treatment of pancreatic cancer2016571022Search in Google Scholar
Manji GA, Olive KP, Saenger YM, Oberstein P. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clin Cancer Res 2017; 23: 1670–8.ManjiGAOliveKPSaengerYMObersteinP.Current and Emerging Therapies in Metastatic Pancreatic Cancer20172316708Search in Google Scholar
Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002; 95 (4 Suppl): 912–22.OettleHRiessH.Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer2002954 Suppl91222Search in Google Scholar
Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013; 30 (1): 361.GunturuKSYaoXCongXThumarJRHochsterHSSteinSMLacyJ.FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity2013301361Search in Google Scholar
Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 2012; 65 (1): 9–22.GrazianiGTentoriLNavarraP.Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer2012651922Search in Google Scholar
Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Front Oncol 2020; 10: 576399.JiangBZhouLLuJWangYLiuCYouLGuoJ.Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?202010576399Search in Google Scholar
Li HY, Qi WL, Wang YX, Meng LH. Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. Genes Dis 2021; 10 (2): 403–14.LiHYQiWLWangYXMengLH.Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead202110240314Search in Google Scholar
Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20 (37): 13343–68.LiuSXXiaZSZhongYQ.Gene therapy in pancreatic cancer201420371334368Search in Google Scholar
Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs 2017; 77: 1091–103.HubbardJMGrotheyA.Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor2017771091103Search in Google Scholar
Pfister C, Schoenemann J. Selenium in Cancer Rehabilitation-A Retrospective Study from a Specialized Clinic. Nutrients 2023; 15 (17): 3827.PfisterCSchoenemannJ.Selenium in Cancer Rehabilitation-A Retrospective Study from a Specialized Clinic202315173827Search in Google Scholar
Lener MR, Scott RJ, Wiechowska-Kozłowska A, Serrano-Fernández P, Baszuk P, Jaworska-Bieniek K, Sukiennicki G, Marciniak W, Muszyńska M, Kładny J, Gromowski T, Kaczmarek K, Jakubowska A, Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat 2016; 48 (3): 1056–64LenerMRScottRJWiechowska-KozłowskaASerrano-FernándezPBaszukPJaworska-BieniekKSukiennickiGMarciniakWMuszyńskaMKładnyJGromowskiTKaczmarekKJakubowskaALubińskiJSerum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer2016483105664Search in Google Scholar
Peng L, Liu X, Lu Q, Tang T, Yang Z. Vitamin E intake and pancreatic cancer risk: a meta-analysis of observational studies. Med Sci Monit 2015; 21: 1249–55.PengLLiuXLuQTangTYangZ.Vitamin E intake and pancreatic cancer risk: a meta-analysis of observational studies201521124955Search in Google Scholar
Stoyanov E, Mizrahi L, Olam D, Schnitzer-Perlman T, Galun E, Goldenberg DS. Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity. Oncotarget 2017; 8 (62): 104772–84.StoyanovEMizrahiLOlamDSchnitzer-PerlmanTGalunEGoldenbergDS.Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity201786210477284Search in Google Scholar
Marley AR, Fan H, Hoyt ML, Anderson KE, Zhang J. Intake of methyl-related nutrients and risk of pancreatic cancer in a population-based case-control study in Minnesota. Eur J Clin Nutr 2018; 72 (8): 1128–35.MarleyARFanHHoytMLAndersonKEZhangJ.Intake of methyl-related nutrients and risk of pancreatic cancer in a population-based case-control study in Minnesota2018728112835Search in Google Scholar
Cencioni C, Trestini I, Piro G, Bria E, Tortora G, Carbone C, Spallotta F. Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches. Nutrients 2022; 14 (8): 1542.CencioniCTrestiniIPiroGBriaETortoraGCarboneCSpallottaF.Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches20221481542Search in Google Scholar
Mitchell T, Clarke L, Goldberg A, Bishop KS. Pancreatic Cancer Cachexia: The Role of Nutritional Interventions. Healthcare (Basel) 2019; 7 (3): 89.MitchellTClarkeLGoldbergABishopKS.Pancreatic Cancer Cachexia: The Role of Nutritional Interventions20197389Search in Google Scholar
Yakovenko A, Cameron M, Trevino JG. Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J Gastrointest Surg 2018; 10 (9): 95–106.YakovenkoACameronMTrevinoJG.Molecular therapeutic strategies targeting pancreatic cancer induced cachexia201810995106Search in Google Scholar
Yun BK, Song M, Hwang HK, Lee H, Lee SM, Kang CM, Lee SM. Potential Nutritional and Metabolomic Advantages of High Fat Oral Supplementation in Pancreatectomized Pancreaticobiliary Cancer Patients. Nutrients 2019; 11 (4): 893.YunBKSongMHwangHKLeeHLeeSMKangCMLeeSM.Potential Nutritional and Metabolomic Advantages of High Fat Oral Supplementation in Pancreatectomized Pancreaticobiliary Cancer Patients2019114893Search in Google Scholar
Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Mori M, Doki Y. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Ann Surg Oncol 2018; 25 (7): 1868–79MukaiYYamadaDEguchiHIwagamiYAsaokaTNodaTKawamotoKGotohKKobayashiSTakedaYTanemuraMMoriMDokiY.Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy2018257186879Search in Google Scholar
Haase VH. The ins and outs of ferric citrate. Kidney Int 2022; 101 (4): 668–70.HaaseVH.The ins and outs of ferric citrate2022101466870Search in Google Scholar
Hanudel MR, Czaya B, Wong S, Jung G, Chua K, Qiao B, Gabayan V, Ganz T. Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease. Sci Rep 2022; 12 (1): 6695.HanudelMRCzayaBWongSJungGChuaKQiaoBGabayanVGanzT.Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease20221216695Search in Google Scholar
Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5. Am J Kidney Dis 2015; 65 (5): 728–36.BlockGAFishbaneSRodriguezMSmitsGShemeshSPergolaPEWolfMChertowGM.A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5201565572836Search in Google Scholar
Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305 (23): 2432–9.IsakovaTXieHYangWXieDAndersonAHSciallaJWahlPGutiérrezOMSteigerwaltSHeJSchwartzSLoJOjoASondheimerJHsuCYLashJLeonardMKusekJWFeldmanHIWolfMChronic Renal Insufficiency Cohort (CRIC) Study GroupFibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease20113052324329Search in Google Scholar
Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91 (8): 3144–9.AntoniucciDMYamashitaTPortaleAA.Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men200691831449Search in Google Scholar
Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011; 108 (46): E1146–1155.FarrowEGYuXSummersLJDavisSIFleetJCAllenMRRoblingAGStayrookKRJideonwoVMagersMJGarringerHJVidalRChanRJGoodwinCBHuiSLPeacockMWhiteKE.Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice201110846E11461155Search in Google Scholar